Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunrise to expand hyperopia laser trials:

This article was originally published in Clinica

Executive Summary

Sunrise Technologies is to expand US trials of its laser treatment for farsightedness after receiving permission from the FDA to test the device in patients with higher levels of hyperopia. The office-based Laser Thermal Keratoplasty system will be assessed in patients with hyperopia from +2.75 to +4.0 dioptres said the Fremont, California-based company. Sunrise has already submitted the device to the agency for approval in patients with hyperopia of between +0.75 and +2.50 dioptres. An FDA-panel is expected to review the premarket approval application in July.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT078274

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel